Defilade Capital Management, L.P.
Reported holdings as of Q2 2026, from 3 quarterly filings.
Holdings
| Security | Ticker | Value | Shares | Weight | Weight change | Held | Change |
|---|---|---|---|---|---|---|---|
| ELI LILLY & CO | LLY | $46.9M | 39,086 | +3.60pp | 3q | +88.9%+$22.1M | |
| PFIZER INC | PFE | $42.7M | 1,771,743 | +2.99pp | 3q | +21.0%+$7.4M | |
| VEEVA SYS INC | VEEV | $42.0M | 236,709 | - | new | NEW | |
| BIOMARIN PHARMACEUTICAL INC | BMRN | $39.0M | 682,005 | - | new | NEW | |
| PTC THERAPEUTICS INC | PTCT | $35.4M | 433,699 | -1.04pp | 2q | +15.3%+$4.7M | |
| BAXTER INTL INC | BAX | $31.1M | 1,459,380 | - | new | NEW | |
| INSMED INC | INSM | $30.0M | 281,838 | -0.45pp | 3q | +44.6%+$9.3M | |
| ZIMMER BIOMET HOLDINGS INC | ZBH | $27.3M | 317,426 | -3.69pp | 2q | -45.2%-$22.5M | |
| INSULET CORP | PODD | $26.9M | 176,932 | - | new | NEW | |
| THERMO FISHER SCIENTIFIC INC | TMO | $26.0M | 51,934 | - | new | NEW | |
| ABBOTT LABORATORIES | ABT | $25.9M | 285,778 | - | new | NEW | |
| ASCENDIS PHARMA A/S | ASND | $25.3M | 94,843 | - | new | NEW | |
| SOLVENTUM CORP | SOLV | $24.4M | 316,454 | - | new | NEW | |
| MEDTRONIC PLC | MDT | $23.7M | 303,301 | - | new | NEW | |
| ELANCO ANIMAL HEALTH INC | ELAN | $21.3M | 864,080 | -0.28pp | 3q | -7.2%-$1.6M | |
| AGIOS PHARMACEUTICALS INC | AGIO | $20.3M | 546,848 | - | new | NEW | |
| ENVISTA HOLDINGS CORPORATION | NVST | $19.1M | 726,108 | - | new | NEW | |
| REVOLUTION MEDICINES INC | RVMD | $15.5M | 82,827 | -2.24pp | 3q | -73.8%-$43.7M | |
| ICU MED INC | ICUI | $15.5M | 105,700 | -2.54pp | 3q | -58.4%-$21.8M | |
| COGENT BIOSCIENCES INC | COGT | $15.2M | 393,441 | +0.13pp | 3q | +11.6%+$1.6M | |
| LANTHEUS HLDGS INC | LNTH | $14.7M | 132,662 | -0.69pp | 2q | -46.8%-$13.0M | |
| OCULAR THERAPEUTIX INC | OCUL | $14.6M | 1,490,286 | +0.19pp | 3q | HELD | |
| ELEDON PHARMACEUTICALS INC | ELDN | $13.9M | 3,525,338 | +0.32pp | 3q | -1.1%-$152.8K | |
| TYRA BIOSCIENCES INC | TYRA | $12.0M | 376,870 | - | new | NEW | |
| OLEMA PHARMACEUTICALS INC | OLMA | $11.6M | 924,758 | -1.60pp | 3q | -38.5%-$7.3M | |
| ORIC PHARMACEUTICALS INC | ORIC | $11.3M | 1,047,690 | +0.02pp | 2q | +24.3%+$2.2M | |
| LARIMAR THERAPEUTICS INC | LRMR | $11.2M | 3,670,135 | - | new | NEW | |
| GLOBUS MED INC | GMED | $11.0M | 139,637 | -2.81pp | 3q | -60.6%-$17.0M | |
| ENOVIS CORPORATION | ENOV | $11.0M | 531,945 | - | new | NEW | |
| EVOMMUNE INC | EVMN | $10.5M | 793,145 | -0.78pp | 3q | +16.9%+$1.5M | |
| TELEFLEX INCORPORATED | TFX | $10.2M | 80,118 | - | new | NEW | |
| DENALI THERAPEUTICS INC | DNLI | $10.1M | 391,866 | -2.32pp | 3q | -71.2%-$24.9M | |
| GLAUKOS CORP | GKOS | $9.3M | 66,519 | - | new | NEW | |
| STAAR SURGICAL CO | STAA | $9.2M | 322,126 | - | new | NEW | |
| PACS GROUP INC | PACS | $9.2M | 215,675 | -2.37pp | 3q | -64.3%-$16.6M | |
| CRINETICS PHARMACEUTICALS IN | CRNX | $9.0M | 239,440 | - | new | NEW | |
| LIVANOVA PLC | LIVN | $8.8M | 107,373 | - | new | NEW | |
| BLACK DIAMOND THERAPEUTICS I | BDTX | $3.1M | 1,674,999 | - | new | NEW | |
| MEREO BIOPHARMA GROUP PLC | MREO | $2.4M | 7,558,756 | -0.03pp | 2q | HELD |
By sector
Industry comes from the SIC code on each company's own SEC filings, which is self-reported and sometimes out of date. Derivative exposure is counted with the shares. Securities the SEC assigns no industry - funds, trusts, foreign issues - are shown as not classified rather than dropped.
| Sector | Value | Share |
|---|---|---|
| Biotech & Pharma | $442.0M | 59.2% |
| Medical Devices | $227.7M | 30.5% |
| Software & IT Services | $42.0M | 5.6% |
| Instruments & Controls | $26.0M | 3.5% |
| Other sectors | $9.2M | 1.2% |
Quarter by quarter
| Quarter | Value | Positions | New | Added | Trimmed | Exited | Top 10 | Days to file |
|---|---|---|---|---|---|---|---|---|
| Q2 2026 | $746.9M | 39 | 20 | 7 | 10 | 12 | 46.5% | 45 |
| Q1 2026 | $712.2M | 31 | 9 | 12 | 10 | 11 | 52.6% | 44 |
| Q4 2025 | $737.7M | 33 | 0 | 0 | 0 | 0 | 55.1% | 44 |
Rows marked UNVERIFIED ID, PLACEHOLDER ID, TICKER AS ID or NON-CUSIP ID carry an identifier that is not a valid CUSIP. They are shown because the filer reported that money, but treat the security named with caution - hover the chip for what is wrong with it, and see the methodology.
Held counts consecutive filings in which this manager reported the position, and can reach further back than the quarters listed above: the tabs begin at Q4 2018 because earlier coverage is too sparse to describe a market, but tenure is counted over every filing we hold, some reaching to 2007. A position sold and later rebought starts again from one.
Weight change is the shift in this position's share of the whole book, in percentage points. It is the more useful column: when money flows into or out of a broad fund, almost every holding is bought or sold at once, so added and trimmed largely track flows. A weight that rose while the book shrank is a decision. Both compare with the previous quarter this filer reported, not the previous calendar quarter.